A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02720263
- Locations
- ๐บ๐ธ
Site US10001, Glendale, California, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02698657
- Locations
- ๐ต๐ฑ
Site PL48011, Krakow, Poland
๐ต๐ฑSite PL48007, Stalowa Wola, Poland
๐ต๐ฑSite PL48003, Warszawa, Poland
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1150
- Registration Number
- NCT02677896
- Locations
- ๐จ๐ฑ
Site CL56003, Santiago, Chile
๐บ๐ธSite US10060, Greenville, North Carolina, United States
๐จ๐ฆSite CA15010, Brampton, Ontario, Canada
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT02674555
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02662582
- Locations
- ๐บ๐ธ
Site US10001, Torrance, California, United States
๐บ๐ธSite US10003, Pittsburgh, Pennsylvania, United States
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02639182
- Locations
- ๐บ๐ธ
Site US01020, Los Angeles, California, United States
๐บ๐ธSite US01004, Ann Arbor, Michigan, United States
๐บ๐ธSite US01008, La Jolla, California, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02610062
- Locations
- ๐จ๐ฆ
Site CA0010, Toronto, Ontario, Canada
๐บ๐ธSite US0001, Houston, Texas, United States
๐บ๐ธSite US0006, Duarte, California, United States
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT02588261
- Locations
- ๐บ๐ธ
Site US10025, Fountain Valley, California, United States
๐บ๐ธSite US10003, Santa Monica, California, United States
๐บ๐ธSite US10013, Aventura, Florida, United States
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02571816
- Locations
- ๐บ๐ธ
Site US10001, Miami, Florida, United States
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
- Conditions
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02561455
- Locations
- ๐บ๐ธ
Site US10005, Phoenix, Arizona, United States
๐บ๐ธSite US10003, Baltimore, Maryland, United States
๐บ๐ธSite US10006, New York, New York, United States